NephroGenex (NRX) Tops Q1 EPS by 4c

NephroGenex (NASDAQ: NRX) reported Q1 EPS of ($0.58), $0.04 better than the analyst estimate of ($0.62).

For earnings history and earnings-related data on NephroGenex (NRX) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94